Type 1 Diabetes and Microscopic Colitis

Note: Values are mean (standard deviation) for "Age at index date" and N (%) for other variables.
Abbreviations: AIDs, autoimmune disorders; CC, collagenous colitis; IBD, inflammatory bowel disease; LC, lymphocytic colitis; MC, microscopic colitis.
^aSub-sample analysed in the medication-adjusted models.
^bIndicating the pre-index diagnosis of any one among thyroiditis, hyperthyroidism, psoriasis, or rheumatoid arthritis.

Note: Values are mean (standard deviation) for "Age at index date" and N (%) for other variables.
Abbreviations: AIDs, autoimmune disorders; IBD, inflammatory bowel disease; MC, microscopic colitis; T1D, type 1 diabetes.
^aIndicating the pre-index diagnosis of any one among thyroiditis, hyperthyroidism, psoriasis, or rheumatoid arthritis.

^aMain analysis comparing cases of microscopic colitis to their matched population controls, adjusted for birth country, education, and pre-index diagnosis of celiac disease, inflammatory bowel disease, asthma, and other autoimmune disorders.
^bSensitivity analysis comparing cases of microscopic colitis to their biopsy-free siblings, adjusted for sex, age at index date, birth country, education, and pre-index diagnosis of celiac disease, inflammatory bowel disease, asthma and other autoimmune disorders, and conditioned on family-cluster.

Note: Values are mean (standard deviation) for "Age at index date" and N (%) for other variables.
Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors; T1D, type 1 diabetes.

Note: Results are estimated from conditional logistic models comparing microscopic colitis patients diagnosed after 2006–01-01 to their matched population controls, adjusting for birth country, education, pre-index diagnosis of seven comorbidities, and corresponding medications prescribed within 6 months before index date.
Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor.

Authors and Disclosures

Xiaoying Kang^1,2, Shengxin Liu¹, Bjorn Roelstraete¹, Hamed Khalili^3–5 and Jonas F. Ludvigsson<sup>1,6

1</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachussets, USA
³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
⁴Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachussets, USA
⁵Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachussets, USA
⁶Department of Pediatrics, Örebro University Hospital, Örebro, Sweden

Correspondence
Xiaoying Kang, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77, Stockholm, Sweden. Email: xiaoying.kang@ki.se

Xiaoying Kang and Shengxin Liu have equal contribution.

Author Contributions
Xiaoying Kang: Conceptualization (lead); formal analysis (equal); investigation (lead); methodology (lead); visualization (equal); writing – original draft (lead). Shengxin Liu: Formal analysis (lead); investigation (equal); methodology (equal); visualization (lead); writing – review and editing (equal). Bjorn Roelstraete: Data curation (lead); investigation (equal); methodology (equal); writing – review and editing (equal). Hamed Khalili: Investigation (equal); methodology (equal); writing – review and editing (equal). Jonas F. Ludvigsson: Conceptualization (lead); data curation (lead); funding acquisition (lead); investigation (equal); project administration (lead); supervision (lead); writing – review and editing (lead).

Conflict of Interest Statement
JFL has coordinated a study on behalf of the Swedish IBD quality register (SWIBREG). That study received funding from Janssen. JFL has also received financial support from MSD developing a paper reviewing national healthcare registers in China. Other authors disclose no conflicts.